However, PSA-based screening for PCa may not only lead to overdiagnosis and overtreatment, but also fail to detect cancer in approximately 15 % of men screened when levels are ≤ 4 ng/mL [2]. The gene discussed is KLK3; the disease is posterior cortical atrophy.